{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:17:46Z","timestamp":1787156266303,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a persistent autoimmune condition marked by systemic inflammation, primarily impacting multiple joints and causing irreversible structural and functional damage. While pathophysiology remains complex, immune cells and cytokines are crucial to the disease\u2019s initiation and progression. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are routinely used to assess disease activity. However, in recent years, the pan-immune inflammatory value (PIV) has emerged as a focal point of inquiry. As a new, single biomarker calculated from various routine blood parameters, PIV accurately reflects the patient\u2019s comprehensive systemic immune-inflammatory condition and offers a more integrated perspective than traditional markers. This article provides a focused analysis of the potential role and clinical significance of PIV in assessing the activity and advancement of RA.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1693676","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:18Z","timestamp":1763529498000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Research advances of pan-immune inflammation value in rheumatoid arthritis"],"prefix":"10.3389","volume":"16","author":[{"given":"Chengmei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu","year":"2021","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.20230801.oo","article-title":"Overview of rheumatoid arthritis and scientific understanding of the disease","volume":"34","author":"Jahid","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80764","article-title":"Beyond the joints: rheumatoid meningitis as a neurological manifestation of rheumatoid arthritis","volume":"17","author":"Gonzalez","year":"2025","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222010922","article-title":"Cytokine networks in the pathogenesis of rheumatoid arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1488790","article-title":"Evaluation of the inhibitory mechanism of Pennisetum glaucum (pearl millet) bioactive compounds for rheumatoid arthritis: an in vitro and computational approach","volume":"15","author":"Sharif","year":"2024","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/cei\/uxac116","article-title":"Preparation of mesoporous silica nanocarriers targeting glucose-6-phosphate isomerase inhibition and application in the treatment of rheumatoid arthritis","volume":"211","author":"Zong","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2016.08.026","article-title":"Oxidative stress modulates the cytokine response of differentiated Th17 and Th1 cells","volume":"99","author":"Abimannan","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.750753","article-title":"B cells in rheumatoid arthritis:Pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33293","article-title":"The role of biologics in rheumatoid arthritis: A narrative review","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121655","article-title":"Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis","volume":"14","author":"Kou","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cancers14112675","article-title":"The association between the pan-immune-inflammation value and cancer prognosis: A systematic review and meta-analysis","volume":"14","author":"Guven","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46609","article-title":"Pan-immune-inflammation index as a biomarker for rheumatoid arthritis progression and diagnosis","volume":"15","author":"Tutan","year":"2023","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1326083","article-title":"Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors","volume":"15","author":"Kuang","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14373","article-title":"Assessment of IL-1\u03b2, IL-6, TNF-\u03b1, IL-8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis","volume":"25","author":"Alturaiki","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001006","article-title":"Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond","volume":"36","author":"Steiner","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004190","article-title":"Fc\u03b3-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis","volume":"10","author":"Andreeva","year":"2024","journal-title":"RMD Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155238","article-title":"Interleukin-6 in rheumatoid arthritis","volume":"21","author":"Pandolfi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11785","article-title":"Citrullinated autoantigen-specific T and B lymphocytes in rheumatoid arthritis: focus on follicular T helper cells and expansion by coculture","volume":"7","author":"Ammon","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.148.10.3133","article-title":"IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function","volume":"148","author":"Ding","year":"1992","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.956127","article-title":"The forgotten key players in rheumatoid arthritis: IL-8 and IL-17 - Unmet needs and therapeutic perspectives","volume":"10","author":"Gremese","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02686079","article-title":"Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools","volume":"32","author":"Steiner","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1737-y","article-title":"Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA","volume":"30","author":"Metawi","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2020.01.007","article-title":"Macrophages regulate the progression of osteoarthritis","volume":"28","author":"Zhang","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.suppl_1.i75","article-title":"Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha","author":"Williams","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1569295","article-title":"Ganoderma lucidum spore powder alleviates rheumatoid arthritis-associated pain hypersensitivity through inhibiting accumulation, N1 polarization, and ROS production of neutrophils in mice","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182923","article-title":"ERK2 and JNK1 contribute to TNF-\u03b1-induced IL-8 expression in synovial fibroblasts","volume":"12","author":"Namba","year":"2017","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.14670\/HH-21.557","article-title":"Angiogenesis in rheumatoid arthritis","volume":"21","author":"Maruotti","year":"2006","journal-title":"Histol Histopathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087925","article-title":"Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037230","article-title":"The relationship between disease activity with pan-immune-inflammatory value and systemic immune-inflammation index in rheumatoid arthritis","volume":"103","author":"Ba\u015faran","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14060634","article-title":"Pan-immune-inflammation value could be a new marker to predict amyloidosis and disease severity in familial mediterranean fever","volume":"14","author":"Ocak","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/art.42674","article-title":"Role and therapeutic potential for targeting fibroblast growth factor 10\/FGFR1 in relapsed rheumatoid arthritis","volume":"76","author":"Meng","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B36","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/196066","article-title":"New inflammatory markers associated with disease activity in rheumatoid arthritis: pan-immune-inflammation value, systemic immune-inflammation index, and systemic inflammation response index","volume":"62","author":"Okutan","year":"2024","journal-title":"Reumatologia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-023-03018-6","article-title":"The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999-2018","volume":"25","author":"Liu","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.55563\/clinexprheumatol\/m46d0v","article-title":"Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis","author":"Lee","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20350-c201611","article-title":"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S477262","article-title":"Application value of platelet-to-lymphocyte ratio as a novel indicator in rheumatoid arthritis: A review based on clinical evidence","volume":"17","author":"Liu","year":"2024","journal-title":"J Inflammation Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1036890","article-title":"Prognostic value of pan-immune-inflammation value in colorectal cancer patients: A systematic review and meta-analysis","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2019.12.010","article-title":"A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer","volume":"20","author":"Pacheco-Barcia","year":"2020","journal-title":"Pancreatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022557","article-title":"Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: A cross-sectional study","volume":"99","author":"Erre","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00766","article-title":"A novel prognostic marker systemic inflammation response index (SIRI) for operable cervical cancer patients","volume":"10","author":"Chao","year":"2020","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005820","article-title":"Decreased GPR55 expression links B-cell activation and vascular remodelling in atherosclerosis in patients with early rheumatoid arthritis","volume":"11","author":"Miranda-Prieto","year":"2025","journal-title":"RMD Open"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70059","article-title":"Aberrant nutrient metabolism in T cells: pathogenesis insight and therapeutic target for autoimmune diseases","volume":"55","author":"Cao","year":"2025","journal-title":"Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1569501","DOI":"10.3389\/fimmu.2025.1569501","article-title":"Breaking the cycle: should we target inflammation, fibrosis, or both","volume":"16","author":"Baxter","year":"2025","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.055","article-title":"Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study","volume":"93","author":"Song","year":"2025","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:18:19Z","timestamp":1763529499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1693676"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1693676","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1693676"}}